Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages

Atyr PHARMA INC (NASDAQ:ATYR) has been assigned a consensus rating of “Buy” from the five research firms that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $19.25.

ATYR has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Leerink Partners initiated coverage on shares of Atyr PHARMA in a research report on Tuesday. They issued an “outperform” rating and a $16.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating on the stock.

Atyr PHARMA Price Performance

Atyr PHARMA stock opened at $3.41 on Tuesday. The firm’s 50-day moving average is $3.55 and its two-hundred day moving average is $2.82. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA has a 12-month low of $1.42 and a 12-month high of $4.22. The stock has a market capitalization of $286.24 million, a P/E ratio of -3.63 and a beta of 1.10.

Institutional Trading of Atyr PHARMA

A number of hedge funds have recently made changes to their positions in ATYR. Federated Hermes Inc. acquired a new position in Atyr PHARMA in the fourth quarter worth $53,093,000. Point72 Asset Management L.P. acquired a new position in Atyr PHARMA in the fourth quarter worth $17,677,000. Tikvah Management LLC acquired a new position in Atyr PHARMA in the fourth quarter worth $8,908,000. Woodline Partners LP acquired a new position in Atyr PHARMA in the fourth quarter worth $6,092,000. Finally, Alyeska Investment Group L.P. acquired a new position in Atyr PHARMA in the fourth quarter worth $4,628,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.